Cancer vaccine fails in CRC but trial yields lessonsJanuary 29, 2019GastroenterologyImmuno-oncologyGastrointestinal Cancer
Novel bispecific CAR shows promise in B-cell malignanciesJanuary 25, 2019Lymphoma & Plasma Cell DisordersImmuno-oncologyImmunotherapy
Uninterrupted ibrutinib with CAR T could improve CLL outcomesJanuary 25, 2019Leukemia, Myelodysplasia, TransplantationImmunotherapyImmuno-oncology
Avelumab active in recurrent or refractory ovarian cancerJanuary 24, 2019Gynecologic CancerImmuno-oncology
Pembrolizumab bests chemo in PD-L1-positive esophageal cancerJanuary 23, 2019GastroenterologyImmuno-oncologyGastrointestinal Cancer
Checkpoint inhibitors linked to rare, but serious immune-related side effectsJanuary 15, 2019Patient & Survivor CareImmuno-oncology
Adverse events a potential concern for chemotherapy-nivolumab in advanced gastric cancerJanuary 10, 2019Immuno-oncologyGastroenterologyGastrointestinal Cancer
No link between sex and survival on checkpoint inhibitors in latest meta-analysisJanuary 7, 2019Lung CancerImmuno-oncology
Armored CAR protects T cells, induces remissionsJanuary 4, 2019Immuno-oncologyLymphoma & Plasma Cell DisordersImmunotherapy
Severe adverse events seen in placebo arm of cancer clinical trialsDecember 13, 2018Immuno-oncologyRenal Cell Carcinoma
PD-L1 expression best predicts response to atezolizumab + nab-paclitaxel for mTNBCDecember 5, 2018Breast CancerImmuno-oncology
Age-related gene expression may affect responses to RCC therapyDecember 4, 2018Renal Cell CarcinomaImmunotherapyGenitourinary CancerImmuno-oncology
JULIET: CAR T cells go the distance in r/r DLBCLDecember 2, 2018Lymphoma & Plasma Cell DisordersImmuno-oncology
Gut bacteria influence HCT outcomesDecember 2, 2018Leukemia, Myelodysplasia, TransplantationImmuno-oncology
